newsfilter
← Latest News
GlobeNewswire·

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of